脂蛋白相关磷脂酶A2与Framingham心血管病危险评分的关系  

Association between lipoprotein-associated phospholipase A2 and Framingham risk score

作　　者：丁耀东 裴昱强 王睿 杨嘉馨 陆世杰 申华[1] 刘晓丽[1] 周玉杰[1] 葛海龙[1] DING Yaodong;PEI Yuqiang;WANG Rui;YANG Jiaxin;LU Shijie;SHEN Hua;LIU Xiaoli;ZHOU Yujie;GE Hailong(Department of cardiology,Beijing Anzhen Hospital,Capital Medical University,Beijing Institute of Heart,Lung and Blood Vesses Diseases,Beijing 100029,China)

机构地区：[1]首都医科大学附属北京安贞医院-北京市心肺血管疾病研究所心内科,100029

出　　处：《心肺血管病杂志》2020年第10期1203-1207,共5页Journal of Cardiovascular and Pulmonary Diseases

基　　金：国家自然科学基金资助(81573744,81973841);国家重点研发计划“精准医学研究”重点专项(2017YFC0908800);北京市医院管理局“使命”计划专项经费(SML20180601);北京市卫生健康委员会科技创新中心建设项目(PXM2019_026272_000006,PXM2019_026272_000005)。

摘　　要：目的:探讨血清脂蛋白相关磷脂酶A2(LP-PLA2)与心血管疾病10年风险评分-Framingham危险评分(FRS)间的相关性,以期能更早期发现心血管疾病中的中高危患者。方法:选取2019年1月至2020年1月,连续纳入于我院行造影检查的170例住院患者,收集患者一般资料及生化指标。依据FRS将患者分为低危组、中危组和高危组。分析LP-PLA2水平与FRS的相关性。应用多因素Logistic回归分析FRS的影响因素。结果:纳入170例患者,平均年龄(61.44±9.50)岁,其中男性103例(60.6%)。将FRS评分结果将患者分为低危组96例(56.5%),中危组60例(35.3%),高危组14例(8.2%),随着心血管疾病风险增高, LP-PLA2水平明显升高,低危组(186.2±81.2)μg/L、中危组(222.4±84.5)μg/L、高危组(236.4±77.6)μg/L(P=0.009)。Spearman分析示LP-PLA2与FRS(r=0.1997,95%CI:0.0462~0.3439,P=0.09)成正相关。多因素回归分析显示,校正混杂因素后,LP-PLA2与心血管疾病风险仍具有相关性。结论:LP-PLA2水平升高与心血管风险严重程度有相关性,提示LPPLA2可作为预测心血管中高危风险的重要指标。Objective: Lipoprotein-associated phospholipase A2(LP-PLA2) has been considered as a potential predictive inflammatory cytokines for the prevention of severe stroke and been found to be associated with atherosclerosis and coronary heart disease in recent years. The purpose of this study was to investigate the association between serum LP-PLA2 and the 10-year cardiovascular disease risk score, the Framingham risk score(FRS), for the early detection of middle and high-risk patients with cardiovascular disease. Methods: In this study, a total of patients admitted to our hospital for coronary radiographic examination in 2019-2020 were successively included, and the demographic information and biochemical indicators of the patients were collected. Then patients were divided into low risk group, medium risk group and high risk group according to the Framingham risk score. Kruskal-wallis rank sum test and chi-square test were used to compare the differences of clinical continuous variable data in each group, and chi-square test was used for categorical variables. Spearman correlation was used to analyze the correlation between LP-PLA2 level and Framingham risk score. Multivariate Logistic regression was used to analyze the influencing factors of Framingham risk score. Results: A total of 170 patients(mean age 61.44±9.50) years were included in the study, including 103(60.6%) males. The FRS score was used to group 96 patients(56.5%) in the low-risk group, 60 in the medium-risk group(35.3%), and 14 in the high-risk group(8.2%). With the increased risk of cardiovascular disease, the lp-pla2 level significantly increased,including low-risk group(186.2±81.2) μg/L、medium-risk group(222.4±84.5) μg/L、high-risk group(236.4±77.6) μg/L(P=0.009). Spearman analysis showed a positive correlation between LP-PLA2 and FRS(r=0.1997,95% CI:0.0462-0.3439, P=0.09).Multivariate regression analysis showed that LP-PLA2 was still associated with cardiovascular disease risk after adjusting for confounding factors. Conclusions: Elevate

关 键 词：脂蛋白相关磷脂酶A2 Framingham危险评分 冠心病 

分 类 号：R54[医药卫生—心血管疾病]